Adicet Bio plans to focus all its resources on advancing the chimeric antigen receptor (CAR)-T cell therapies, ADI-001, and ADI-270, after pausing the development of its preclinical programme for ADI-925.
CAR-T cell therapies have been identified as a key immuno-oncology innovation area by GlobalData. The CAR-T cell market is expected to be worth $25bn by 2028, as per GlobalData analysis.
GlobalData is the parent company of Clinical Trials Arena.
ADI-001 clinical trial update
ADI-001 is a CAR-T cell therapy that targets CD20. It is being evaluated as treatment for relapsed or refractory B-cell malignancies, including non-Hodgkin’s lymphoma (NHL), in a Phase I clinical trial (NCT04735471). The trial is currently recruiting patients with mantel cell lymphoma, a type of B-cell lymphoma, as per an 8 November press release.
Adicet has also initiated an expansion cohort (EXPAND) as part of the Phase I trial and plans to evaluate patients with larger B-cell lymphoma (LBCL) post-CAR-T cell therapy. The company also expanded its manufacturing capabilities to accommodate additional demand.
The company plans to provide a clinical update on the Phase I study in H2 2024. It plans to advance the drug under an accelerated approval pathway to Phase II trial in post-CAR-T LBCL and/or MCL patients.
Preclinical pipeline update
Adicet plans on developing ADI-270 for treating renal cell carcinoma, with potential in other solid tumour indications. ADI-270 is a CD70 targeting CAR-T cell therapy.
The company received positive feedback from the US Food and Drug Administration (FDA) during the pre-IND meeting. It plans to file an investigational new drug (IND) for ADI-270 with the FDA in H1 2024.
Adicet had cash reserves of $183.3m as of 30 September 2023. These are expected to fund operations into H1 2025. The company has a market cap of $61.42m.
Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
